The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search

table 1

Neurovisual Impairment: A Frequent Complication of Alpha-Interferon Treatment in Chronic Viral Hepatitis

table  1.   Clinical and Laboratory Characteristics of Patients Studied


Parameter Patients (n = 53)

Sex (% males) 27 (50.9%)
Age (yrs)* 52.5 ± 14.4 (55, 16-74)
Type of viral hepatitis
  HBV-positive (n, %) 22 (41.5%)
  HCV-positive (n, %) 31 (58.5%)
Presence of cirrhosis (n, %) 24 (45.3%)
  Child-Pugh scoredagger 5 (5-12)
Baseline diabetes (n, %) 4 (7.5%)Dagger
Baseline hypertension (n, %) 13 (24.5%)
Baseline serum cholesterol 240 mg% (n, %) 3 (5.7%)
Baseline total cholesterol/HDL ratio >5 (n, %) 9 (17.0%)
Baseline AST (IU/ml)*   95 ± 88 (74.5, 17-555)
Interferon-a2b dose per injection (MU)*,§  3.2 ± 0.7 (3, 1.2-5)
Cumulative interferon dose (MU)*,#  386 ± 150 (392, 96-762)
Total interferon treatment time (months)*,# 10.2 ± 3.4 (11, 1.8-18.3)

* Mean ± SD, (median, range).
dagger Median (range).
Dagger Four additional patients (7.5%) had positive oral glucose tolerance test.
§ Administered thrice weekly.
#Up to the second ophthalmological evaluation.

Return To Article